These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1053 related items for PubMed ID: 7784479

  • 1. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA.
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [Abstract] [Full Text] [Related]

  • 2. Contribution of bradykinin to the cardiovascular effects of ramipril.
    Linz W, Wiemer G, Schölkens BA.
    J Cardiovasc Pharmacol; 1993 Mar; 22 Suppl 9():S1-8. PubMed ID: 7514234
    [Abstract] [Full Text] [Related]

  • 3. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W, Schölkens BA.
    J Cardiovasc Pharmacol; 1992 Mar; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [Abstract] [Full Text] [Related]

  • 4. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W, Martorana PA, Schölkens BA.
    J Cardiovasc Pharmacol; 1990 Mar; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [Abstract] [Full Text] [Related]

  • 5. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C, Seidl U, Reinecke A, Riester U, Graf K, Schultheiss HP, Hilgenfeldt U, Unger T.
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.
    Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P, Unger T, Schölkens BA.
    Mol Cell Biochem; 2003 Mar; 147(1-2):89-97. PubMed ID: 7494560
    [Abstract] [Full Text] [Related]

  • 7. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.
    Linz W, Wiemer G, Schölkens BA.
    Diabetes; 1996 Jan; 45 Suppl 1():S51-8. PubMed ID: 8529801
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.
    Linz W, Wiemer G, Schölkens BA.
    Braz J Med Biol Res; 1994 Aug; 27(8):1949-54. PubMed ID: 7749386
    [Abstract] [Full Text] [Related]

  • 11. Kinin-related effects of angiotensin-converting enzyme inhibition.
    Bönner G.
    Clin Physiol Biochem; 1990 Aug; 8 Suppl 1():6-15. PubMed ID: 2257722
    [Abstract] [Full Text] [Related]

  • 12. [Do kinins have significance for the antihypertensive effect of angiotensin-converting enzyme inhibitors?].
    Bönner G.
    Z Kardiol; 1988 Aug; 77 Suppl 3():23-7. PubMed ID: 3062958
    [Abstract] [Full Text] [Related]

  • 13. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.
    Weckler N, Leitzbach D, Kalinowski L, Malinski T, Busch AE, Linz W.
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):191-6. PubMed ID: 14608526
    [Abstract] [Full Text] [Related]

  • 14. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
    Zhang X, Recchia FA, Bernstein R, Xu X, Nasjletti A, Hintze TH.
    J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
    [Abstract] [Full Text] [Related]

  • 15. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
    Nolly H, Miatello R, Damiani MT, Abate CD.
    Immunopharmacology; 1997 Jun; 36(2-3):185-91. PubMed ID: 9228545
    [Abstract] [Full Text] [Related]

  • 16. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.
    Gohlke P, Linz W, Schölkens B, Van Even P, Martorana P, Unger T.
    Br J Clin Pract Suppl; 1996 Jul; 84():1-10. PubMed ID: 8994995
    [Abstract] [Full Text] [Related]

  • 17. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.
    Linz W, Wiemer G, Schölkens BA.
    J Mol Cell Cardiol; 1992 Aug; 24(8):909-19. PubMed ID: 1331474
    [Abstract] [Full Text] [Related]

  • 18. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ.
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [Abstract] [Full Text] [Related]

  • 19. Kinin- and non-kinin-mediated interactions of converting enzyme inhibitors with vasoactive hormones.
    Kramer HJ, Glänzer K, Meyer-Lehnert H, Mohaupt M, Predel HG.
    J Cardiovasc Pharmacol; 1990 Apr; 15 Suppl 6():S91-8. PubMed ID: 1697369
    [Abstract] [Full Text] [Related]

  • 20. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA, Derkx FH, van den Meiracker AH.
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.